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Abstract:  Acyclic nucleoside phosphonates (ANPs) represent a well-defined class of clinically used 
nucleoside analogues. All ANPs need intracellular phosphorylation before they can bind viral DNA 
polymerases. Recently, a novel class of alpha-carboxynucleoside phosphonates  (α-CNPs) have been 
designed to mimic the natural 2’-deoxynucleotide 5’-triphosphate substrates of DNA polymerases. 
They contain a carboxyl group in the phosphonate moiety linked to the nucleobase through a cyclic 
or acyclic bridge. α-CNPs act as viral DNA polymerase inhibitors without any prior requirement of 
metabolic conversion. Selective inhibitory activity against retroviral reverse transcriptase and 
herpesvirus DNA polymerases have been demonstrated. These compounds have a unique 
mechanism of inhibition of viral DNA polymerases, and provide possibilities for further modifications 
to optimize and fine-tune their anti-viral DNA polymerase spectrum. 
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Introduction 
Acyclic nucleoside phosphonates (ANPs) represent a well-defined structural class of compounds that 
were originally reported in the eighties [1]. Several members of this class of compounds were shown 
to have antiviral or anticancer activity. Distinct subclasses of (acyclic) nucleoside analogues have 
been identified depending on the molecular nature of the acyclic entity linked to the nucleobase. 
Each of them possesses well-defined antiviral efficacies. The first compound reported to be inhibitory 
to a broad range of DNA viruses (predominantly including herpesviruses, poxviruses and 
adenoviruses) was (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [designated as (S)-HPMPA 
and belonging to the subclass of 3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives] (1) (Fig. 
1). Its cytosine counterpart (S)-HPMPC [2] was the first acyclic nucleoside phosphonate licensed for 
clinical use (designated as cidofovir or Vistide®). It has a similar broad anti-DNA virus spectrum as (S)-
HPMPA but it was particularly active against human cytomegalovirus (HCMV) [2,3]. It is therefore 
clinically used for the treatment of HCMV retinitis in AIDS patients, although this drug is currently 
also used off-label for the treatment of human papilloma virus, poxvirus and adenovirus infections 
[4]. 
 A second subclass of ANPs has a 2-phosphonylmethoxyethyl (PME) moiety linked to the 
nucleobase (Fig. 1) [5]. The prototype compound, designated PMEA [9-(2-
phosphonylmethoxyethyl)adenine] proved particularly active against herpesviruses but also 
retroviruses (such as HIV) and hepadnaviruses, represented by hepatitis B virus (HBV) [5-7]. Although 
active in HIV-infected individuals, the compound proved toxic at the indicated efficacy dose. 
However, it was also found active against HBV-infected individuals at markedly lower doses, and 
therefore, the compound has been approved for HBV treatment (designated as adefovir, Hepsera®) 
[8]. Whereas within the HPMP-subclass of ANPs both purine (i.e. adenine, 2,6-diaminopurine, 
guanine) and pyrimidine (i.e. cytosine) derivatives showed antiviral activity, only purine nucleobase 
derivatives such as adenine, 2,6-diaminopurine, guanine, and 6-cyclopropyladenine, but not 
pyrimidine nucleobase derivatives, showed antivirally activity within the subclass of PME-derivatives. 
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 A third subclass of ANPs consists of a 2-phosphonylmethoxypropyl (PMP-) entity linked to the 
nucleobase [9] (Fig. 1). As observed for the PME derivatives, only PMP derivatives containing a purine 
nucleobase are antivirally active. The adenine derivative (R)-PMPA (tenofovir, Viread®) was selected 
within the PMP subclass of ANPs as a clinical candidate for the treatment of retrovirus (i.e. HIV) and 
HBV infections, and currently acts as a cornerstone for HIV (and HBV) treatment. 
 Several other distinct groups of ANPs have been reported to be endowed with antiviral 
activity in cell culture and in animal models but have not (yet) been advanced for clinical use. They 
contain either a (S)-HPMP, a PME or a (R)-PMP structural moiety linked to a modified (non-natural) 
nucleobase. One of such well-defined group of compounds contain a 2,4-diaminopyrimidine linked 
through an oxygen atom to the HPMP, PME or PMP part of the molecule (designated HPMP-DAPym, 
PME-DAPym or PMP-DAPym) (Fig. 1) [10,11]. The DAPym derivatives display an antiviral activity 
spectrum predominantly similar to their corresponding adenine derivatives, probably because the 
DAPym configuration molecularly mimics an (incomplete) adenine nucleobase [12] allowing 
hydrogen pairing to a pyrimidine nucleobase in the viral nucleic acid chain.  
Another well-defined group of compounds contain a triazine (i.e. 5-azacytosine as the nucleobase) 
linked to the HPMP moiety [(S)-HPMP-5-azaC] (Fig. 1) [13,14]. The antiviral activity spectrum of the 
HPMP-5-azaC derivative parallels that of (S)-HPMPC [15].  
Only a few cyclic nucleoside phosphonates have been reported to be endowed with pronounced 
antiviral potential. The phosphonylmethoxy-2’-fluoro-2’,3’-didehydro-2’,3’-dideoxyadenosine (Fd4A-
phosphonate; GS-9148) (Fig. 1) has shown to possess interesting anti-HIV activity in cell culture [16]. 
An IND was filed in December 2016 for treatment of patients with NRTI mutations in combination 
with other antiretroviral drugs [17,18]. 
In conclusion, a variety of ANPs have been demonstrated to be particularly successful and/or 
promising to be developed for clinical use. The market for the currently available clinically used 
acyclic nucleoside phosphonates against HIV and HBV is tremendous. According to the WHO, It is 
estimated that around 37 million individuals are infected with HIV, and at least 2 billion individuals 
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are infected with HBV worldwide of which 240 million people are chronically infected. Product gross 
sales for the treatment of HIV and HBV infections by the acyclic nucleoside phosphonate drug 
tenofovir, its prodrugs tenofovir disoproxil fumarate and tenofovir alafenamide, and its combinatory 
formulations amounted up to 18 billion US dollars in 2016. 
 
The mechanism of antiviral action of ANPs 
The most important feature of the ANPs is the presence of a phosphonate entity that is isosteric with 
the phosphate group of the natural nucleoside 5’-monophosphates but consists of a P-C-O bond 
instead of a P-O-C ester bond. In this respect, the phosphonate entity in the ANPs is highly stable and 
does not easily hydrolyse. Therefore, the ANPs can be considered as highly stable dNMP derivatives. 
 All ANPs require cellular uptake, and obligatory metabolic conversion to their corresponding 
diphosphate derivatives (the equivalent of the natural 2’-deoxynucleoside 5’-triphosphates) to be 
antivirally active [19,20]. The metabolic activation is catalyzed by cellular enzymes and the 
conversion of the ANPs to their active diphosphates occurs in two separate steps. Only under this 
metabolically activated form, they compete with the natural 2’-deoxyucleotide-5’-triphosphates 
(dNTPs) for interaction with the viral (and cellular) DNA polymerases. In this respect, they not only 
inhibit the normal catalytic function of these DNA polymerases, but additionally, the activated ANPs 
are also incorporated into the viral DNA chain. Such incorporation eventually results in obligatory 
viral DNA chain termination and thus in premature abortion of the viral DNA chain elongation 
[21,22]. 
 Due to their anionic nature, ANPs are not very efficiently taken up by the (virus-infected) 
cells and display rather poor oral bioavailability. Therefore, a number of prodrugs have been 
designed to increase the clinical efficacy of these molecules (Figs. 1, 2 and 3). In this respect, 
alkyloxyalkyl derivatives of (S)-HPMPC (i.e. HDP-(S)-HPMPC) [23], the bis(pivaloyloxymethyl) ester of 
PMEA (i.e. adefovir dipivoxil) [24], the bis(isopropyloxycarbonyloxymethyl) ester of (R)-PMPA 
formulated as its fumarate salt (tenofovir disoproxil fumarate) (TDF) [25], the alaninyl 
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phenylphosphonoamidate isopropyl ester of tenofovir  (TAF) [26] and the hexadecyloxypropyl 
derivative of tenofovir (CMX-157) [27] have been successfully designed to afford a more efficient 
cellular uptake, increased oral bioavailability and, in case of TAF, also prolonged retention of the drug 
in peripheral lymphocytes [28]. 
 
Design of the alpha-carboxynucleoside phosphonates (α-CNPs) 
Most recently, an entirely different structural class of (cyclic and acyclic) nucleoside phosphonates 
has been designed, synthesized and thoroughly investigated [29-32]. It consists of a nucleobase part 
to allow Watson-Crick base-pairing with the template strand in the viral DNA polymerase, a 
phosphonate moiety containing a carboxylate function in addition to the phosphonate group and a 
variable linker entity between the nucleobase and the carboxy phosphonate part (Fig. 4). This linker 
originally consisted of a cyclopentyl entity (resulting in the prototype of the subclass of the cyclic α-
CNPs) [30] but later on it was also replaced by a more flexible acyclic aliphatic chain (i.e. butenyl) 
(resulting in the prototype of the subclass of the acyclic α-CNPs) (Fig. 4) [32].  
To avoid the requirement for metabolic activation, the carboxy phosphonate moiety was designed to 
potentially act as a mimic for the triphosphate present in the natural dNTP substrates of DNA 
polymerases. The requirements for such a triphosphate mimic were multiple: (i) efficient Mg++ 
hexacoordination between the triphosphate mimic and active site amino residues of the DNA 
polymerase must be feasible as also required for efficient interaction between the dNTPs and the 
DNA polymerase enzyme active site. It was assumed that the carboxylate in the phosphonate moiety 
might contribute to coordinate Mg++; (ii) the α-carboxy phosphonate entity must be chemically stable 
under physiological conditions and should be tightly linked to the other part of the nucleoside 
molecule; (iii) the molecule must enable efficient canonical Watson-Crick base pairing with the 
template overhang and (iv) the distance between, and the positions of, the nucleobase and the 
triphosphate mimic should resemble as closely as possible the natural situation where a 2-
deoxyribose is bridged between both parts of the molecule. However, the 2-deoxyribose could not 
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be  incorporated in the inhibitor structures because of the intrinsic lability of the ether oxygen that 
links the pentose to the phosphonate. Therefore, a cyclopentyl ring was used in the first syntheses to 
represent the linker moiety. This cyclopentyl entity was earlier proven to fulfill these criteria in the 
nucleoside reverse transcriptase inhibitors (NRTI) carbovir and abacavir [33,34]. Later on, compounds 
were also designed to replace the cyclopentyl by an acyclic aliphatic entity, preferably a butenyl 
group since this moiety replacing the 2-deoxyribose in nucleotide analogues had previously been 
shown to generate compounds with antiherpetic activity [35] (Fig. 4). All natural nucleobases, in 
addition to several unnatural nucleobases, and modifications in the carboxy phosphonate part, have 
been designed and synthesized using the α-CNP concept [30,32,36,37,38]. 
 
Synthesis of carbocyclic α-CNPs 
The synthesis of the first-generation series of carbocyclic α-CNPs [30] involved two key transition-
metal-catalysed steps: first, rhodium-catalysed carbenoid O–H insertion to install the 
carboxyphosphonate (building on our earlier work [29] attaching this moiety to protected nucleoside 
derivatives), and then palladium-catalysed Tsuji–Trost allylation to install the nucleobase. The 
remaining manipulations required to afford the desired products were catalytic hydrogenation and 
final deprotection using TMSBr to cleave the methyl phosphonate then NaOH to cleave the 
carboxylate ester (Fig. 5). The highly polar α-CNPs were purified using charcoal chromatography. This 
sequence is advantageous since the common building block 2 can be converted into several α-CNP 
derivatives by varying the nucleobase used in the allylation step. By this method, derivatives of 
nucleobases U, T, C, A, and 5-FU were synthesised. 
As the first-generation route was not applicable to the synthesis of the guanine α-CNP derivative, 
other routes were developed to allow the preparation of this compound [38], thereby increasing the 
scope and applicability of the synthetic methodology.  
Racemic G-α-CNP was obtained from a cyclopentylamine via initial base construction followed by O–
H insertion (Fig. 6). In the last step, TMSBr conveniently removed Boc protection as well as cleaving 
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the methyl phosphonate and aqueous NaOH cleaved the carboxylate ester and also converted the 
chloro-purine moiety to guanine. The racemic G-α-CNP was also prepared from allylic acetate 1 by 
introducing the base first then installing the phosphonate (Fig. 7), effectively a reversal of the key 
steps in the first generation synthesis. D and L forms of G-α-CNP were prepared using this route by 
employing the appropriate enantiomer of 1. 
All of the cyclic α-CNP compounds were prepared in racemic DL form, and separately as D and L 
forms by using the appropriate enantiopure precursor 1 in each instance. In all cases, the α-CNPs 
were formed as mixtures of diastereomers at the carboxyphosphonate group. 
By omitting the NaOH hydrolysis step during the deprotection sequence it was possible to prepare 
the partially-deprotected esters 4, and also the unsaturated carbocyclic α-CNP 5 was prepared from 
the intermediate 3 with a slight modification of the deprotection reaction conditions. 
Other variations on the CNP motif that were prepared (Fig. 8) include the bisphosphonate 6, 
malonate 7, and the carboxylic acid compound without the phosphonate function 8; these 
derivatives were prepared using the same synthetic approach, by substituting the appropriate diazo 
precursor into the rhodium-catalysed O–H insertion reaction [36]. 
 
Synthesis of acyclic (butenyl) α-CNPs 
Based on the synthetic approach described above for the cyclic α-CNPs, the synthesis of acyclic 
(butenyl) α-CNPs involved three steps starting with the O-H insertion of the rhodium carbenoid 
generated from trimethyl phosphonodiazoacetate. The rhodium catalysed (1 mol% of Rh2(OAc)4) 
reaction of but-2-ene-1,4-diol 9 with trimethyl phosphonodiazoacetate 10 was carried out in 
refluxing benzene (Fig. 9). Upon completion of the reaction, mono- (11) and di- (12) O-H inserted 
compounds were isolated in 58 and 19% yield, respectively. 
The second step of the synthetic route involved the Mitsunobu reaction for the attachment of 
different nucleobases to the butenyl carboxyphosphonate moiety 11. The Mitsunobu reaction was 
initiated by generating the betaine (PPh3:DIAD) by treating PPh3 and DIAD in dry THF at 0oC.  To 
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another reaction vessel at -40oC containing the O-H inserted compound 3 and the corresponding 
protected nucleobases 12a-12d in THF, this betaine was added. The reaction mixture was allowed to 
warm to room temperature and stirring continued for 24 hours. On completion of the reaction the 
expected nucleobase-substituted carboxyphosphonates 13a-13d were isolated in moderate to good 
yields (Fig. 10). 
Finally, a two step-deprotection of compounds 13a-13d was carried out in one pot. An excess of 
TMSBr followed by water was used to deprotect the dimethoxyphosphonate entity. An excess of 
aqueous 1M NaOH was used to saponificate the carboxyester and to debenzoylate the N-3-
benzoylthymine. A charcoal column was used for  purification of the phosphononucleosides 14a-14d 
with a 1:1 mixture of EtOH and 20% aqueous ammonia (Fig. 11).  
 
Anti-viral DNA polymerase activity of α-CNPs 
The cyclic α-CNPs containing a natural pyrimidine or purine nucleobase were invariably inhibitory 
against HIV-1 reverse transcriptase in the presence of their corresponding homopolymeric 
template/primer (Table 1). Thus, the thymine containing T- α-CNP inhibited HIV-1 RT in the 
nanomolar range in the presence of poly rA.dT, but not in the presence of other homopolymeric 
template/primers such as poly rI.dC, poly rU.dA or poly rC.dG. These findings point to selective 
recognition and canonical base-pairing of the T- α-CNP analogue with an adenine base present in the 
template overhang. In this respect, the α-CNPs behave similarly as the NRTIs and N(t)RTIs with 
respect of HIV RT recognition and inhibition [31,37]. The α-CNPs generally proved equally potent 
inhibitors of HIV-1 RT as their corresponding 2’,3’-dideoxynucleotide analogues such as AZT-TP, 
ddCTP, ddATP and ddGTP. It was also shown that the α-CNPs inhibited other retrovirus-encoded RTs 
such as those derived from HIV-2, SIV, FIV and Visna virus [31]. 
 In contrast to HIV RT inhibition, the cyclic α-CNPs were much less potent inhibitors of 
herpetic DNA polymerases derived from herpes simplex virus type 1 (HSV-1), human cytomegalovirus 
(HCMV) or varicella-zoster virus (VZV) (Table 2) [31]. Their 50%-inhibitory concentration (IC50) values 
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were in the middle micromolar range. Only the G- α-CNP analogue had an IC50 in the low micromolar 
range [37]. Strikingly, both the cellular DNA polymerases α and β were poorly inhibited by the cyclic 
α-CNPs (IC50 >100 µM). So far , the potential inhibitory activity of the α-CNPs against other cellular 
DNA polymerases, including the mitochondrial DNA polymerase gamma and the DNA polymerases 
delta , epsilon and zeta have not been investigated. It can not be excluded that the α -CNPs are 
recognized as inhibitors of one or several of these enzymes as well, which may result in potential 
side-effects. Therefore, it would be warranted to investigate the potential interaction of α-CNPs with 
these enzymes and defining the structure-activity relationships of the inhibitors for these enzymes in 
order to identify and select the most specific inhibitors of the viral DNA polymerases for further 
clinical development.  
 The acyclic (butenyl) α-CNPs showed an opposite inhibitory selectivity [32]. Whereas they 
generally poorly inhibited HIV-1 RT (IC50 >100 µM in virtually all cases) (Table 3), they markedly 
gained inhibitory activity against the herpetic DNA polymerases (Table 4). All acyclic (butenyl) α-CNPs 
inhibited the herpetic DNA polymerases in the lower micromolar range, irrespective the nature of 
the nucleobase (only the C- α-CNP analogue was slightly less effective against HSV-1 and HCMV DNA 
polymerases, but kept pronounced inhibitory activity against VZV DNA polymerase). As also observed 
for all cyclic α-CNPs, the acyclic α-CNPs poorly inhibited the cellular DNA polymerases α and β (IC50 
≥500 µM) (with the exception of moderate inhibition of DNA polymerase α by the butenyl-T- α-CNP 
(Table 4).  
 An interesting feature was observed for the acyclic (butenyl) α-CNPs. Whereas the cyclic α-
CNPs inhibited HIV-1 RT in a highly selective manner (specific competition in the presence of a 
natural dNTP containing a similar nucleobase as the α-CNP), the acyclic (butenyl) α-CNPs behaved 
clearly differently [37]. They efficiently inhibited the herpetic DNA polymerases (i.e. HCMV and VZV 
DNA polymerases) irrespective of the nature of the nucleobase in the competing dNTP (Table 5). 
Therefore, it could be concluded that the acyclic (butenyl) α-CNPs must interact with the herpetic 
DNA polymerases in a kinetic manner that is clearly different than observed for the cyclic α-CNPs 
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against HIV-1 RT. An overview of the most important kinetic properties of the α-CNPs against HIV RT 
is provided in Table 6. 
 
Molecular interactions of α-CNP in the substrate-binding site of HIV-1 reverse transcriptase.  
Structural studies were performed to ascertain the molecular interactions of T-α-CNP with HIV-1 RT. 
Crystal structures of the ternary RT/dsDNA/T-α-CNP and RT/DNA-aptamer/T-α-CNP complexes were 
determined [31,39]. These investigations clearly showed that (i) the thymine nucleobase of T-α-CNP 
base-paired with the adenine overhang of the template, (ii) the cyclopentyl ring interacted with 
active site amino acids in a similar manner as the 2-deoxyribose does in the dNTP/enzyme 
interactions, (iii) only the L form of the synthesized T-α-CNP racemic mixture (L/D) is the active 
constituent, and (iv) the α-carboxymethylphosphonate part of the molecule actively participated in 
the hexa-coordination of both catalytic Mg2+  ions at the polymerase active site, mimicking the 
coordination of a dNTP substrate.  One carboxy oxygen and two phosphonate oxygens of T-α-CNP 
chelate the Mg2+ ions in a manner analogous to the chelation of an oxygen atom from the alpha, beta 
and gamma phosphates of dNTP by the Mg2+ ions ( Fig 12), however, spatial positions of the three 
chelating atoms of T-α-CNP are different from those of a dNTP. The chelated carboxyphosphonate 
entity is not susceptible to hydrolysis by the RT enzyme and thus, forms a non-productive ternary 
complex with RT, leading to inhibition of the catalytic function of the enzyme as a competitive 
inhibitor. These structural findings explain the direct-acting inhibitory activity of the α-CNPs against 
HIV RT and defined the unique characteristics of this class of molecules. The concomitant presence 
and availability of three negatively charged oxygens in the carboxyphosphonate part of the α-CNP 
molecule effectively compensate for the chelation of the phosphates of a dNTP.  In agreement with 
the crystal structures, substitutions of the negative charge of the carboxy group or the two negative 
charges of the phosphonate group by methyl ester groups [31] caused a complete loss of their 
inhibitory potential against HIV-1 RT.  Also, the bisphosphonate 6, the malonate 7 and the carboxylic 
acid compound without the phosphonate function 8 showed poor, if any inhibitory activity against 
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HIV RT. These findings also demonstrate that any synthesis of novel α-CNP derivatives should take 
these requirements into consideration while designing and generating active molecules. 
 
Similarities between α-CNPs and NcRTIs for interaction with HIV reverse transcriptase. 
Beside the nucleoside RT inhibitors (NRTIs), non-nucleoside RT inhibitors (NNRTIs), pyrophosphate 
inhibitors and RNAseH inhibitors of HIV RT, nucleotide-competing RT inhibitors (NcRTIs) have been 
reported. INDOPY (indolopyridinone) is the prototype compound of this peculiar class of RT inhibitors 
(Fig 13) [40], and several other structures have since then been reported as NcRTIs [41,42]. Although 
the NcRTIs have a structure that is entirely different from the classical nucleotide structure, they 
interact, alike the NRTIs, with the substrate-binding site of HIV RT in a competitive manner with the 
natural dNTP substrates. However, unlike the NRTIs, the NcRTIs do not incorporate into the viral 
growing DNA chain. Thus, in this respect, α-CNPs are reminiscent of the mechanism of action 
reported for the NcRTIs in that they reversibly interact with the substrate-binding site of RT in a 
competitive manner with the incoming dNTPs and bind to the post-translocated RT/nucleic acid 
complex conformation. However, whereas the α-CNPs can only form stable ternary complexes with 
HIV RT when the nucleobase in the α-CNP is complementary to the templating nucleobase (indicative 
for Watson-Crick base pairing), the NcRTIs form a stable ternary complex irrespective of the nature of 
the templating nucleobase. The α-CNPs also differ from the NcRTIs in that they obligatorily require 
hexacoordination with Mg2+ (like NRTIs and the natural dNTPs) whereas Mg2+ is not required for the 
binding of the NcRTIs with HIV RT. A last striking difference between α-CNPs and the NcRTIs is the 
fact that α-CNPs can also interact with other viral DNA polymerases (i.e., herpetic DNA polymerases) 
and even with dNTP-interacting enzymes different from DNA polymerases (see below), whereas 
NcRTIs are solely and exclusively specific for reverse transcriptases. 
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Different kinetic interactions of α-CNPs with viral DNA polymerases depending the nature of the 
enzyme 
When cyclic α-CNPs were investigated for their interaction with HIV-1 reverse transcriptase in kinetic 
and biochemical assays, it was demonstrated that they showed competitive inhibition with respect of 
the natural dNTP substrate, and obligatory binding of the template/primer to the enzyme prior to 
efficient binding of the α-CNP to the enzyme [31,37]. The α-CNPs reversibly inhibited the RT enzyme. 
Specific Watson-Crick base-pairing was required for inhibition, but there was no indication of 
incorporation of the α-CNP into the growing DNA chain (in contrast with NRTIs and N(t)RTIs). It 
should also be noticed that solely the L-enantiomer but not the D-enantiomer of α-CNPs showed 
significant activity against HIV-1 RT [31,37]. 
 The kinetic picture seems entirely different for the interaction of the cyclic α-CNPs and the 
acyclic (butenyl) α-CNPs with the herpetic DNA polymerases. First of all, both the L- and D-
enantiomers of the cyclic G- α-CNP equally inhibited herpetic (i.e. HSV-1, HCMV) DNA polymerases 
[37]. They did so in a non- or uncompetitive manner. These findings indicate that the interaction of 
the L- and D- α-CNPs must occur at a location that is different from the herpetic DNA polymerase 
substrate active site. Also, the acyclic (butenyl) α-CNPs (as demonstrated for the T analogue) non-
competitively inhibited the VZV DNA polymerase, showing identical (non-competitive) kinetics as the 
cyclic T- α-CNP. The inhibition proved independent of the nature of the nucleobase (Table 5). 
Moreover, evidence was provided that inhibition of HCMV DNA polymerase occurred independent of 
Watson-Crick base-pairing. Taken all available data together, α-CNPs seem to bind to an enzyme site 
that differs from the active substrate-binding site of the DNA polymerase. It is possible that these 
compounds selectively bind to the 3’,5’-exonuclease active center of the herpetic DNA polymerases 
or to a yet unknown binding site. For inhibition of the herpetic DNA polymerases Watson-Crick base-
pairing was not strictly required. Therefore, the aromatic ring system might be further modified and 
optimized in the cyclic and acyclic α-CNPs to allow inhibitor structures that are markedly different 
from the natural nucleobase entity and nucleotide structure. 
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Drug resistance characteristics of α-CNPs 
The cyclic α-CNPs containing the four natural nucleobases have been explored for their inhibitory 
potential against HIV reverse transcriptase that contain amino acid mutations that are 
characteristically selected by established clinically-used drugs [37] (Table 7). The highest resistance 
profile for the G-α-CNP derivative was observed for the F61A (79-fold), V75I (8.7-fold), M184I (19-
fold) and M184V (8.7-fold) mutant enzymes. However, in some cases, sensitization was observed (i.e. 
K70E (0.7-fold) and K70Q (0.7-fold), but not K70R (2.6-fold)). The structural and biochemical data 
show that α-CNPs bind HIV-1 RT like a nucleoside triphosphate mimic. As expected, the dNTP-binding 
pocket mutations have varying degrees of effect on the binding, and consequently on the inhibitory 
potency of α-CNPs (Table 7). The mutations that have the highest effect on the efficacy of α-CNPs are 
M184V/I and F61A. The M184V/I mutation appears to discriminate the L-nucleoside inhibitors 
lamivudine (3TC) and emtricitabine (FTC) by a steric hindrance mechanism [43,44]. The analogous 
mutation in hepatitis B virus DNA polymerase also develops resistance to 3TC and FTC by a similar 
mechanism [45]. The crystal structure of the RT/DNA/T-α-CNP complex [22] suggests a similar 
mechanism of resistance to α-CNPs that contain a cyclopentyl ring extending towards the branched 
side-chain of the M184V/I mutation in HIV-1 RT. Instead, the, F61A mutation in the fingers 
subdomain of HIV-1 RT may affect the positioning of the nucleobase of α-CNPs due to loss of 
interaction between F61 and V74. 
 Interestingly, the fold-resistance/sensitization against a well-defined amino acid mutation 
was shown to differ depending the nature of the nucleobase in the α-CNP molecule. For example, 
whereas G-α-CNP showed 79-fold resistance to F61A, the A-α-CNP derivative was only 3.9-fold 
resistant. Also, the G-α-CNP proved 19- and 8.7-fold less sensitive to M184I and M184V RT, 
respectively, whereas the A-α-CNP was only 2.8- and 1.7-fold less sensitive to these RT mutations. 
Similar observations could be made for the degree of sensitization for K65E and K65Q RT, which 
showed 3- to 3.7-fold resistance for A-α-CNP but 3- to 5-fold sensitization for C-α-CNP. The observed 
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differences in resistance/sensitivity profile of α-CNPs depending the nature of both the mutation in 
the enzyme and the nature of the nucleobase in the α-CNP molecule opens interesting perspectives 
for the potential of combination therapy within the α-CNP class of compounds. 
 
Lipophilic prodrugs of α-CNPs 
So far, no antiviral (i.e. HIV, herpesviruses) activity has been observed for the α-CNPs in cell culture. 
This may most likely be due to the highly anionic nature of the compounds. In comparison to the 
classical acyclic nucleoside phosphonates who have two negative charges exposed in the molecule at 
the phosphonate site, the α-CNPs contain even an additional negative charge, derived from the 
carboxy group in the phosphonate part. This makes these molecules rather unlikely candidates for 
penetrating membranes of their target cells. To increase cellular uptake and oral bioavailability in 
vivo, the clinical candidates of the acyclic nucleotide phosphonates have been converted to lipophilic 
prodrugs before administration. Their structures are shown in Figs. 1-3.  
Synthesis and investigation of the antiviral activity of pro-drugs of the α-CNPs, using known and 
novel prodrug approaches, is underway in an attempt to deliver the free α-CNPs into the intact cells.  
In fact, the most obvious prodrug derivatives to be made for the α-CNPs to increase lipophilicity and 
cellular uptake are those that have been currently used to increase cellular uptake and oral 
bioavailability of the clinically approved acyclic nucleoside phosphonates. They include a HDP ( 
hexadecyloxypropyl ) group as in HDP-(S)-HPMPC , a BisPOM (Bis((pivaloyloxy)methoxy)) entity as in 
Adefovir dipivoxil , a BisPOC (Bis(isopropoxycarbonyloxymethyl) ) moiety as in Tenofovir disoproxil 
fumarate or an arylisopropylalaninylphosphoramidate configuration as in Tenofovir alafenamide (Fig. 
1). Covering the anionic charge of the alpha-carboxyl in α-CNPs by a methyl group has been tried but 
proven unsuccessful to generate antiviral activity , most likely due to the lack of efficient release of 
the methyl group after exposure of the prodrug to the cellular environment. Generation of an α-CNP 
with a free negatively charged carboxyl group has indeed earlier been shown to be crucial for 
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efficient interaction with the DNA polymerases. Alternatively, other types of drug formulations, 
including liposome preparations containing the α-CNPs should be explored, both in vitro and in vivo. 
 
Inhibitory activity of α-CNPs against enzymes other than viral DNA polymerases. 
DNA polymerases are enzymes for which the dNTPs act as substrates for incorporation into the 
growing DNA chain. However, many enzymes are also feedback-regulated by dNTPs under the 
conditions in which dNTPs are not to be hydrolyzed but act as such. In nucleotide metabolism, there 
are numerous examples of such feedback mechanisms. 
Two of such well-known interactions are dTTP feedback inhibition of thymidine kinase activity, and 
dCTP-triggered stimulation of dCMP deaminase. Interestingly, it could be demonstrated that T-α-CNP 
containing thymine as nucleobase  (not α-CNPs with other nucleobases) was able to inhibit the 
activity of mitochondrial TK-2 and to a somewhat lesser extent the herpesvirus-encoded TKs [31]. 
The cytosolic TK-1 seemed not to be affected by T-α-CNP. These data demonstrate again that subtle 
differences between enzymes eventually determine the potential of interaction with α -CNPs. Also 
for dCMP deaminase, it was found that C-α-CNP, which contains cytosine as the nucleobase, but not 
the other α-CNPs, was able to inhibit this enzyme in the presence of the natural dCTP stimulator [31]. 
The C-α-CNP derivative as such had no stimulatory activity. The findings that enzymes other than 
DNA polymerases interact with dNTPs for regulatory purposes, may be subject of inhibition by α-
CNPs. It is of interest to notice that dCMP deaminase plays a role in the conversion of anticancer 
drugs such as araC and gemcitabine to their (deaminated) inactive form, and thus, it may be 
speculated that in such case C-α-CNPs may have a potentiating effect on these anticancer 
compounds if combined. Thus, these findings may open new perspectives for interfering with cellular 
functions by α-CNPs, and such possibilities are worth to be further explored. It may broaden the 
potential application of the α-CNPs to other fields in addition to the antiviral domain. 
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Future Perspectives 
The α-CNPs represent a novel class of stable carboxy nucleoside phosphonates that directly 
interact with their target (viral DNA polymerases) without the requirement of prior metabolic 
activation (phosphorylation). The lack of obligatory metabolic conversion prior to become active 
against its target avoid variability in activity due to different metabolic properties inherent to the 
phase of the cell cycle and different cell types to which the α-CNPs are exposed. They also distinguish 
themselves among the nucleoside phosphonates in that any nucleobase shows inhibitory activity, 
whereas it is usually only the adenine derivative within the PME and PMPA, and adenine and 
cytosine derivatives within the HPMP subclass of ANPs that show pronounced antiviral activity. 
Therefore, the structure-activity relationship is considerably broader than the current ANPs, which 
allow a better fine-tuning of the optimal structure of the α-CNPs and thus a higher selectivity for 
each of its potential targets. 
 The α-CNPs have so far only been explored for their inhibitory activity against retroviral and 
herpetic DNA polymerases. It may be assumed that they should also be active against hepatitis B 
virus DNA polymerase because this enzyme has also a reverse transcriptase function. However, 
beside HBV DNA polymerase, other viral DNA polymerases, including poxvirus and adenovirus DNA 
polymerases, should be preferentially investigated for their sensitivity to the inhibitory activity of α-
CNPs. 
 Given the importance of the current configuration of the α-carboxy phosphonate part of the 
molecule to act as dNTP mimics and direct inhibitors of DNA polymerases, pronounced modifications 
at this part of the α-CNP molecule might compromise their inhibitory potential. The bridge between 
the α-carboxy phosphonate and the nucleobase should also be the subject of further modifications. 
Given the fact that replacement of the cyclopentyl by the aliphatic butenyl entity shifts the selectivity 
spectrum of the α-CNPs from HIV- to herpesvirus-encoded DNA polymerases, a broad variety of 
novel cyclic and acyclic bridges should be explored to further fine-tune their observed inhibitory 
activities and also to define the structure-activity relationship of the α-CNPs against other DNA 
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polymerases. In addition, the search for other DNA polymerases should be further extended to viral 
RNA polymerases as well, since the principle of required Mg2+-hexacoordination for efficient dNTP (α-
CNP) binding to the substrate-active polymerase site also accounts for NTP binding to RNA 
polymerases. 
 Our findings that the nature of the nucleobase in the α-CNPs is not crucial for recognition by 
herpetic DNA polymerases (in contrast with HIV reverse transcriptases) open interesting perspectives 
for replacing the natural nucleobases such as thymine, cytosine, adenine and guanine by other 
heterocycles (i.e. substituted purines and pyrimidines, pyridines, pyrroles, thiophenes, etc.) or even 
non-heterocycles with or without the presence of functional groups. Such novel α-CNP derivatives 
may make the molecules more simple and straightforward in terms of synthesis and possibly more 
inhibitory. 
 The major drawback so far seems to be efficient delivery of the α-CNPs into their target 
(virus-infected) cells to enable intracellular inhibition of the viral DNA polymerases. Therefore, 
synthetic efforts are currently devoted to the synthesis of prodrugs that may shield part or all of the 
negative charges of these molecules to allow efficient cellular uptake and intracellular delivery of the 
free α-CNPs. Alternatively, physical technologies to deliver anionic molecules into cells (i.e. liposome 
formulations) should be explored. 
 
Executive summary 
Design of the alpha-carboxynucleoside phosphonates (α-CNPs) 
• α-CNPs represent a novel synthetic scaffold of viral DNA polymerase (i.e. HIV reverse 
transcriptase and herpetic DNA polymerase) inhibitors. They are structurally simple nucleoside 
monophosphonate analogues that contain an additional carboxyl group in the phosphonate 
moiety and a cyclic or acyclic entity that bridges the carboxy phosphonate with the nucleobase. 
Anti-viral DNA polymerase activity of α-CNPs 
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• In contrast with the classical acyclic nucleoside phosphonates (ANPs), the α-CNPs do not require 
any prior metabolic conversion (phosphorylation) to exert their inhibitory activity against viral 
DNA polymerases. As a consequence, the α-CNPs function as direct-acting inhibitors of viral DNA 
polymerases. 
• Binding of the α-CNPs in the HIV RT substrate (dNTP) binding site is nucleobase-specific and 
selectively competes with an incoming dNTP containing a similar nucleobase as the α-CNP. 
• Binding of the α-CNPs to the herpesvirus DNA polymerases is not nucleobase-specific and does 
not compete efficiently with an incoming dNTP. 
• In contrast with NRTIs and N(t)RTIs, α-CNPs are not incorporated into the growing viral DNA 
chain. 
Molecular interaction of α-CNP in the substrate-binding site of HIV-1 reverse transcriptase 
• The α-carboxy group on the phosphonate provides an oxygen that is equivalent to an oxygen of 
the α-phosphate moiety in natural dNTPs for the obligatory Mg2+-hexacoordination in the 
substrate binding site of HIV RT. Two oxygens of the phosphonate group of the α-CNPs have a 
similar function as the oxygens of the β- and γ-phosphates in dNTPs for efficient octahedral 
coordination of both Mg2+ ions. 
Different kinetic interactions of α-CNP with viral DNA polymerases depending the nature of the 
enzyme 
• Whereas cyclic α-CNPs preferentially inhibit retroviral (i.e. HIV) RTs, the acyclic (butenyl) α-CNPs 
shift their inhibitory selectivity spectrum to herpetic DNA polymerases. Both cyclic and acyclic α-
CNPs show poor, if any, inhibitory action against cellular DNA polymerases α and β. 
Inhibitory activity of α-CNPs against enzymes other than viral DNA polymerases 
• Specific interactions of α-CNPs with enzymes that do not use dNTPs as a substrate but rather as a 
regulatory (feedback) mechanism have been shown and open new perspectives to broaden the 
biological fields of application of the α-CNPs. 
Lipophilic prodrugs of α-CNPs 
19 
 
• None of the α-CNPs show antiviral activity in cell culture, presumably due to the overall strong 
negative charge of the α-CNP molecules and consequently lack of efficient uptake by virus-
infected cells. Initial attempts of the synthesis of α-CNP prodrugs that have been designed to 
cover (neutralize) the negative charges of the carboxy-phosphonate moiety has not yet resulted 
in active antiviral compounds in cell culture; further prodrug approaches are under investigation. 
• Adapted prodrug moieties or other technologies may be required to efficiently internalize the α-
CNPs into their target cells. 
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Abbreviations 
ANP, acyclic nucleoside phosphonate; CNP, carboxynucleoside phosphonate; HIV, human 
immunodeficiency virus; HSV, herpes simplex virus; HCMV, human cytomegalovirus; VZV, varicella 
zoster virus; HPMPA, 9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine; HPMPC, 1-(3-hydroxy-2-
phosphonylmethoxypropyl)cytosine; PMEA, 9-(2-phosphonylmethoxyethyl)adenine; HBV, hepatitis B 
virus; PMPA, 9-(2-phosphonylmethoxypropyl)adenine; DAPym, 2,4-diaminopyrimidine; IND, 
investigational new drug; RT, reverse transcriptase; NRTI, nucleoside reverse transcriptase inhibitor; 
N(t)RTI, nucleotide reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase 
inhibitor; TDF, tenofovir disoproxil fumarate; TAF, tenofovir alaninyl phenylphosphonoamidate 
isopropyl ester; dNTP, 2’-deoxynucleotide-5’-triphosphate; 5-FU, 5-fluorouracil; dsDNA, double 
stranded DNA; NcRTI, nucleotide-competing reverse transcriptase inhibitor; INDOPY, 
indolopyridinone. 
 
Figure legends 
Fig. 1. Structural formulae of the prototypes of subclasses of acyclic nucleoside phosphonates and 
their corresponding clinically used lipophilic prodrugs. 
Fig. 2. Structural formulae of acyclic nucleoside phosphonates with modified nucleobase. 
Fig. 3. Structural formulae of a cyclic nucleoside phosphonate and corresponding lipophilic 
phosphonoamidate prodrug. 
Fig. 4. Structural formulae of cyclic and acyclic α-CNPs. 
Fig. 5. First-generation synthesis of cyclic α-CNP compounds. 
Fig. 6. Synthesis of G-α-CNP by base construction. 
Fig. 7. Synthesis of G-α-CNP by Tsuji-Trost allylation. 
Fig. 8. Variations on the CNP motif. 
Fig. 9. O-H insertion of rhodium carbenoid. 
Fig. 10. Mitsunobu reaction for the attachment of the nucleobase. 
Fig. 11. Deprotection of α-carboxy nucleoside phosphonates 13a-13d. 
Fig. 12. Structural basis for T-α-CNP inhibition of HIV RT. Mode of binding of T-α-CNP to RT/dsDNA 
and RT/DNA-aptamer complexes shown in yellow and cyan, respectively (left); two catalytic ions (A 
and B) are present in the RT/DNA-aptamer/T-α-CNP complex.  
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A schematic comparison of the structural interactions of T-α-CNP (center) and the natural dTTP 
(right) with HIV-1 RT and the template/primer. The hexacoordination of metal ions A and B (Mg2+) is 
shown. The contribution of the oxygens of the carboxylic acid and the phosphonate groups in α-CNP 
are shown (center), to be compared with the contribution of the oxygens of the triphosphate group 
in the natural dNTP substrate (right). 
Fig. 13. Structural formula of the NcRTI INDOPY-1 (5-methyl-1-(4-nitrophenyl)-2-oxopyrido[3,2-
b]indole-3-carbonitrile). 
 
Table Legends 
• Table 1. Inhibitory activity of the L-enantiomeric α-CNPs against HIV-1 RT in the presence of 
different homopolymeric template/primers 
• Table 2. Inhibitory activity of the L-enantiomeric α-CNPs against viral and cellular DNA 
polymerases 
• Table 3. Inhibitory activity of acyclic (butenyl) α-CNPs against HIV-1 RT in the presence of 
different homopolymeric template/primers. 
• Table 4. Inhibitory activity of acyclic (butenyl) α-CNPs against viral and cellular DNA polymerases 
• Table 5. Inhibitory activity of acyclic (butenyl) α-CNPs in herpetic DNA polymerase assays using 
different dNTP substrates. 
• Table 6. Comparative overview of the properties of α-CNPs and other HIV RT inhibitor classes. 
• Table 7. Fold-resistance of the α-CNPs against mutant HIV-1 RTs compared to wild-type (control). 
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Graphical Abstract: 
 
 
• Direct inhibitors of viral DNA polymerases without need for metabolic conversion.
• Interaction through Mg2+ hexacoordination at the substrate-active site of HIV RT.
• Interaction with herpes DNA polymerases at a non-substrate-active site.
• Any purine or pyrimidine nucleobase result in active compounds.
• Cyclic α-CNPs generally more selective for HIV RT; acyclic α-CNPs more selective
  for herpes DNA polymerases.
NucleobaseO
P
O O
O
-
O O
-
O
P
O O
O
-
O O
-
Nucleobase
Cyclic α-CNP Acyclic (butenyl) α-CNP
 
  
36 
 
Table 1. Inhibitory activity of the L-enantiomeric α-CNPs against HIV-1 RT in the presence of different 
homopolymeric template/primers 
Compounda IC50b,c HIV-1 reverse transcriptase (µM) 
 poly rA.dT 
([3H]dTTP) 
poly rI.dC 
([3H]dCTP) 
poly rU.dA 
([3H]dATP) 
poly rC.dG 
([3H]dGTP) 
T-α-CNP 0.41 >500 155 >100 
U-α-CNP 3.0 >500 208 - 
C-α-CNP 164 4.3 45 - 
A-α-CNP >500 >500 0.19 - 
G-α-CNP 396 - - 0.43 
AZT-TP 0.11 - - - 
ddCTP - 14 - - 
ddATP - - 1.5 - 
ddGTP - - - 0.41 
 
aEach α-CNP represents as a pair of diastereomers at the alpha-carboxy stereocenter. 
b50% Inhibitory concentration, or compound concentration required to inhibit DNA polymerase 
activity by 50%. 
Inhibition of RTs by T-, U-, C-, A- and G-α-CNP analogues was evaluated using the respective 
homopolymeric template/primers poly rA.dT (for T- and U-α-CNP), poly rI.dC (for C-α-CNP), poly 
rU.dA (for A-α-CNP) and poly rC.dG (for G-α-CNP) and ∼1.25-2.5 µM of their appropriate 
corresponding dNTP substrates [CH3-3H]dTTP (for T- and U-α-CNP), [5-3H]dCTP (for C-α-CNP), [2,8-
3H]dATP (for A-α-CNP) and [2,8-3H]dGTP (for G-α-CNP). 
cData taken from references 31 and 37. 
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Table 2. Inhibitory activity of the L-enantiomeric α-CNPs against viral and cellular DNA polymerases 
Enzyme source IC50a,b DNA polymerase (µM) 
 T-α-CNP C-α-CNP A-α-CNP G-α-CNP 
HIV-1 RT 0.41 4.3 0.19 0.43 
HSV-1 DNA pol 26 19 23 4.2 
HCMV DNA pol 38 17 23 20 
VZV DNA pol 38 - - - 
DNA pol α 229 269 171 121 
DNA pol β >200 ≥200 >200 522 
a50% Inhibitory concentration. 
bData taken from reference 31 and 37. 
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Table 3. Inhibitory activity of acyclic (butenyl) α-CNPs against HIV-1 RT in the presence of different 
homopolymeric template/primers 
Compound IC50a,b HIV-1 reverse transcriptase (µM) 
 poly rA.dT 
([3H]dTTP) 
poly rI.dC 
([3H]dCTP) 
poly rU.dA 
([3H]dATP) 
poly rC.dG 
([3H]dGTP) 
Butenyl T-α-CNP 235 >500 ≥500 >500 
Butenyl C-α-CNP 270 >500 273 >500 
Butenyl A-α-CNP 404 >500 40 >500 
Butenyl G-α-CNP ≥500 >500 369 >500 
a50%-inhibitory concentration. 
bData taken from reference 32. 
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Table 4. Inhibitory activity of acyclic (butenyl) α-CNPs against viral and cellular DNA polymerases 
Enzyme source IC50a,b DNA polymerase (µM) 
 Butenyl T-α-CNP Butenyl C-α-CNP Butenyl A-α-CNP Butenyl G-α-CNP 
HSV-1 DNA pol 3.7 12 2.7 2.1 
HCMV DNA pol 2.1 16 5.5 3.6 
VZV DNA pol 2.2 2.9 3.3 2.9 
DNA pol α 14 414 ≥500 365 
DNA pol β >500 >500 454 >500 
 
a50%-inhibitory concentration. 
bData taken from reference 32. 
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Table 5. Inhibitory activity of acyclic (butenyl) α-CNPs in herpetic DNA polymerase assays using different dNTP 
substrates 
Nucleobase IC50 (µM)a,b 
 HCMV DNA polymerasec  VZV DNA polymerased 
 [3H]dTTP [3H]dCTP [3H]dATP [3H]dGTP  [3H]dTTP 
Butenyl T-α-CNP 2.1 3.0 3.1 2.5  2.2 
Butenyl A-α-CNP 5.5 2.9 3.0 3.2  3.3 
Butenyl G-α-CNP 3.6 11 10 14  2.9 
Butenyl C-α-CNP 16 20 33 30  2.9 
a50%-inhibitory concentration. 
bData taken from reference 32. 
cTemplate/primer: activated calf thymus DNA, [3H]dNTP substrate + three nonradiolabeled dNTPs. 
dTemplate/primer: poly dA.oligo dT, [3H]dTTP substrate. 
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Table 6. Comparative overview of the properties of α-CNPs and other HIV RT inhibitor classes 
 α-CNPa NRTIb NtRTIc NNRTId 
Nucleoside 
structure 
No Yes No No 
Nucleotide 
structure 
Yes No Yes No 
Metabolic 
activation required 
No Yes 
(3 steps) 
Yes 
(2 steps) 
No 
Enzyme inhibition 
versus dNTP 
substrate 
Competitive Competitive Competitive Non-competitive 
Binding to RT 
substrate-binding 
site 
Yes Yes Yes No 
Nature of the RT 
binding 
Mutually 
exclusive with 
dNTP, but 
coordinating with 
Mg2+ 
Mutually 
exclusive with 
dNTP, but 
coordinating 
with Mg2+ 
Mutually 
exclusive with 
dNTP, but 
coordinating with 
Mg2+ 
Mutually non-
exclusive with 
dNTP and Mg2+ 
Nucleobase-specific 
binding to template 
Yes Yes Yes No 
DNA chain 
termination 
No Yes Yes No 
Selective for HIV-1 
RT 
No No No Yes 
 
aα-Carboxynucleoside phosphonate. 
bNRTI: nucleoside RT inhibitor (e.g. zidovudine triphosphate). 
cNtRTI: nucleotide RT inhibitor (e.g. tenofovir diphosphate). 
dNNRTI: non-nucleoside RT inhibitor (e.g. nevirapine or rilpivirine). 
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Table 7. Fold-resistance of the α-CNPs against mutant HIV-1 RTs compared to wild-type (control) 
Mutation in 
HIV-1 RT 
G-α-CNP 
Poly rC.dG 
[3H]dGTP 
A-α-CNP 
Poly rU.dA 
[3H]dATP 
C-α-CNP 
Poly rI.dC 
[3H]dCTP 
T-α-CNP 
Poly rA.dT 
[3H]dTTP 
F61A 79 3.9 5.2 31 
K65R 2.1 0.8 1.6 1.5 
K70E 0.7 3.0 0.2 0.8 
K70Q 0.7 3.7 0.3 1.1 
K70R 2.6 3.3 2.3 0.9 
V75I 8.7 7.0 6.0 2.6 
L100I 5.2 3.0 0.5 1.4 
K103N 1.1 0.6 1.5 0.6 
V106A 1.6 0.8 0.2 1.1 
Y115F 2.3 0.8 1.1 2.4 
E138K 0.9 0.7 1.5 1.0 
Q151M 3.1 0.8 0.4 3.1 
Y181C 5.2 1.8 1.5 0.9 
M184I 19 2.8 12 36 
M184V 8.7 1.7 11 16 
 
Data taken from reference 37. 
 
 
